WebOct 24, 2012 · Ticagrelor, a cyclopentyl-triazolo-pyrimidine acting as an analogue of adenosine triphosphate (ATP), constitutes a first non-thienopyridine direct platelet P2Y12 receptor blocker. Recognition of the fact that ATP competitively inhibits ADP-induced platelet aggregation encouraged attempts to identify its stable and potent analogue. WebOct 4, 2024 · Ticagrelor (Brillinta), also known as AZD6140, is an oral compound belonging to the class of cyclopentyl triazolo-pyrimidine. It is also metabolized via hepatic bioconversion to form an active metabolite . Like the thienopyridines, ticagrelor also directly but reversibly binds to the P 2 Y 12 receptor on platelet.

Pharmacodynamic Properties of Antiplatelet Agents - Medscape

WebMar 1, 2014 · FDA. The PLATelet Inhibition and Clinical Outcomes (PLATO) trial was designed as a phase 3, randomized, double blind, parallel-group, multinational, clinical study, comparing the efficacy of ticagrelor (formerly known as AZD6140, and currently marketing as Brilinta®) versus standard care treatment with clopidogrel. WebNov 1, 2010 · Ticagrelor (AZD6140), a cyclopentyl-triazolo-pyrimidine, is the first orally available antagonist of the ADP receptor of the P2Y12 subtype. Ticagrelor inhibits … new orleans vacation with teens

US Patent Application for Treating Cardiac Arrhythmias, Heart …

WebIt is a cyclo-pentyltriazolo-pyrimidine that reversibly inhibits the P2Y 12 receptor. References ^ a b Alexopoulos, Dimitrios (2014). "P2Y12 Receptor Inhibitors in Acute … Web[0004] Ticagrelor is a cyclo-pentyltriazolo-pyrimidine that reversibly inhibits the P2Y 12 receptor which is a protein found mainly but not exclusively on the surface of blood platelets and which is an important regulator in blood clotting. [0005] The chemical name of ticagrelor is (1 S,2S,3R,5S)-3-[7-[(1 R,2S)-2-(3,4-Difluorophenyl ... Webチエノピリジン. チエノピリジン とは、窒素を1つ含む六員環芳香族化合物である ピリジン と、硫黄を1つ含む五員環芳香族化合物である チオフェン が、環の1辺を共有して 縮 … new orleans va hospital human resources